Study
Regenerative Neural Stem Cell Therapy Improves Multidomain Neurological Deficits after Traumatic Brain Injury in Nonhuman Primates
In 18 marmosets with traumatic brain injury, a 5-million-cell cryopreserved human neural stem-cell dose improved several behavioral and MRI measures without observed tumors over three months.
Summary Can transplanted human stem cells help monkeys recover after traumatic brain injury? Show / hide ↓
Researchers studied 18 common marmosets, small monkeys, with brain injuries caused by a controlled cortical impact, a carefully measured blow to the brain. Seven weeks later, they injected the injured area with either an inactive fluid, 1 million human neural stem cells, or 5 million cells, which are intended to support or replace damaged nerve cells. All animals received tacrolimus, a medicine that reduces immune rejection. After three months, monkeys given 5 million cells performed better on thinking tasks, walking tests, anxiety-like behavior, and sleep-wake activity than the other groups. MRI, a detailed brain scan, also showed smaller injury areas and better preservation of white matter, the brain tissue that connects regions; no tumors were seen.
What this means for you: This is early animal evidence, not proof that the treatment works or is safe in people. Do not buy or seek stem-cell treatment based on this study, because it was small, lasted only three months, and used brain injections plus immune-suppressing drugs.
early evidenceM Arredondo and colleagues tested a cryopreserved, GMP-like human neural stem-cell product called pd.S6.133.hNSC in 18 common marmosets after controlled cortical impact. Seven weeks after injury, animals received MRI-guided stereotactic transplantation into the perilesional cortex. Vehicle, 1 million cells, and 5 million cells were compared under tacrolimus immunosuppression. At three months, the 5-million-cell group improved executive and problem-solving performance, gait dynamics, anxiety-like behavior, and actigraphy-derived sleep-wake measures relative to vehicle and the lower dose. Serial 7-T MRI showed a dose-dependent reduction in lesion volume and preservation of corpus-callosum white-matter volume. The authors reported no observed adverse events over 1,197 cumulative post-transplant animal-days. Histopathology showed engraftment without tumor formation or abnormal tissue overgrowth at three months. This is a preprint in nonhuman primates. It does not establish human efficacy, long-term tumor safety, or a clinically practical delivery protocol. It supports further translational work, not clinic treatment.
These findings support the safety and multidomain efficacy of a cryopreserved hNSC product in a nonhuman primate TBI model and inform translational development toward first-in-human testing with clinically aligned endpoints.
Preprint, nonhuman primate study with N=18 and three-month follow-up. Tacrolimus immunosuppression and stereotactic surgery may limit clinical generalizability. Long-term tumor, ectopic tissue, and functional durability data are not available.
Cited by
2 encyclopedia entries reference this study.